Home › Esophageal Adenocarcinoma › Illinois › Joliet
Esophageal Adenocarcinoma clinical trials in Joliet, IL
3 studies for Esophageal Adenocarcinoma are looking for participants at sites in and around Joliet (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
RecruitingPhase 2/3
- Northwestern Medicine Orland Park, Orland Park · 14 mi away
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
RecruitingPhase 3
- UC Comprehensive Cancer Center at Silver Cross, New Lenox · 6 mi away
- University of Chicago Medicine-Orland Park, Orland Park · 14 mi away
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecruitingPhase 1
- University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox · 6 mi away
- The University of Chicago Medicine Center for Advanced Care Orland Park, Orland Park · 14 mi away
Esophageal Adenocarcinoma trials in other cities
- New York City, NY18 studies
- Boston, MA13 studies
- Houston, TX12 studies
- Nashville, TN11 studies
- Arlington, VA11 studies
- Durham, NC10 studies
- Jacksonville, FL9 studies
- Baldwin Park, CA9 studies
- Rochester, MN9 studies
- St. Louis, MO9 studies
- Queens, NY9 studies
- Los Angeles, CA9 studies
Other studies in Joliet
- Lung Cancer12 studies
- Non-Small Cell Lung Cancer12 studies
- Bladder Cancer7 studies
- Metastatic Cancer7 studies
- Head and Neck Squamous Cell Carcinoma6 studies
- Prostate Cancer5 studies
- Acute Myeloid Leukemia5 studies
- Hypopharyngeal Cancer5 studies
- Laryngeal Cancer5 studies
- Oral Cancer5 studies
- Breast Cancer4 studies
- Ovarian Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.